At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
oxybutynin and clonidine oral solution treatment A +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Double-blind, Randomized, Placebo-controlled 4-way Crossover Study to Evaluate the Relative Efficacy and Safety of OC Oral Solution (Oxybutynin and Clonidine) for Sialorrhoea in Patients With Parkinson's Disease
In Brief
A Phase 2 clinical trial evaluating oxybutynin and clonidine oral solution treatment A, oxybutynin and clonidine oral solution treatment B, and 2 other interventions for Sialorrhoea. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether OC (oxybutynin and clonidine) oral solution is effective in reducing saliva secretion in patients suffering from Parkinson's Disease with excessive salivation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSialorrhoea
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 2011
Enrollment StartAug 2011
Primary CompletionSep 2012
TodayJul 2026
First PostedJun 10, 2011
Enrollment StartAug 1, 2011
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.1 years ago
Interventions
oxybutynin and clonidine oral solution treatment Adrug
oxybutynin and clonidine oral solution treatment Bdrug
oxybutynin and clonidine oral solution treatment Cdrug
oxybutynin and clonidine oral solution treatment Ddrug
Placebo